MedKoo Cat#: 576800 | Name: Itasetron hydrochloride monohydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Itasetron hydrochloride monohydrate is a potent 5HT-3 receptor antagonist.

Chemical Structure

Itasetron hydrochloride monohydrate
Itasetron hydrochloride monohydrate
CAS#138602-61-6

Theoretical Analysis

MedKoo Cat#: 576800

Name: Itasetron hydrochloride monohydrate

CAS#: 138602-61-6

Chemical Formula: C16H23ClN4O3

Exact Mass: 354.1459

Molecular Weight: 354.83

Elemental Analysis: C, 54.16; H, 6.53; Cl, 9.99; N, 15.79; O, 13.53

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Itasetron hydrochloride hydrate; Itasetron hydrochloride monohydrate; Itasetron HCl monohydrate
IUPAC/Chemical Name
1H-Benzimidazole-1-carboxamide, 2,3-dihydro-N-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-2-oxo-, monohydrochloride, monohydrate, endo-
InChi Key
UZOZFPGVCIJZKM-NXNLNBCESA-N
InChi Code
InChI=1S/C16H20N4O2.ClH.H2O/c1-19-11-6-7-12(19)9-10(8-11)17-15(21)20-14-5-3-2-4-13(14)18-16(20)22;;/h2-5,10-12H,6-9H2,1H3,(H,17,21)(H,18,22);1H;1H2/t10-,11+,12-;;
SMILES Code
O.Cl.CN1[C@@H]2CC[C@H]1C[C@H](C2)NC(=O)N3C(=O)Nc4ccccc34
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 354.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Patoia L, Del Favero A, Giglietti A, Malacarne P, Donati D, Indelli M, Bensi G, Palladino MA, Cigarini P, Kempe R, Voigt T. Intravenous itasetron: establishing the effective dose range for the prophylactic control of acute emesis in cancer patients undergoing high-dose cisplatin chemotherapy. Clin Oncol (R Coll Radiol). 1999;11(2):99-104. PubMed PMID: 10378635. 2: Goldschmidt H, Salwender H, Egerer G, Kempe R, Voigt T. Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy. Anticancer Drugs. 1997 Jun;8(5):436-44. PubMed PMID: 9215605. 3: Volonté M, Ceci A, Borsini F. Effect of the 5-hydroxytryptamine3 receptor antagonist itasetron (DAU 6215) on (+)-N-allylnormetazocine-induced dopamine release in the nucleus accumbens and in the corpus striatum of the rat: an in vivo microdialysis study. J Pharmacol Exp Ther. 1995 Oct;275(1):358-67. PubMed PMID: 7562571. 4: Pitsikas N, Borsini F. Itasetron (DAU 6215) prevents age-related memory deficits in the rat in a multiple choice avoidance task. Eur J Pharmacol. 1996 Sep 12;311(2-3):115-9. PubMed PMID: 8891590. 5: Itasetron. DAU 6215, U 98079. Drugs R D. 1999 Oct;2(4):243-4. PubMed PMID: 10659399. 6: Pitsikas N, Brambilla A, Borsini F. DAU 6215, a novel 5-HT3 receptor antagonist, improves performance in the aged rat in the Morris water maze task. Neurobiol Aging. 1993 Nov-Dec;14(6):561-4. PubMed PMID: 8295658. 7: Schiavi GB, Brunet S, Rizzi CA, Ladinsky H. Identification of serotonin 5-HT4 recognition sites in the porcine caudate nucleus by radioligand binding. Neuropharmacology. 1994 Mar-Apr;33(3-4):543-9. PubMed PMID: 7984293. 8: Sagrada A, Turconi M, Bonali P, Schiantarelli P, Micheletti R, Montagna E, Nicola M, Algate DR, Rimoldi EM, Donetti A. Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation. Cancer Chemother Pharmacol. 1991;28(6):470-4. PubMed PMID: 1834359. 9: Invernizzi R, Pozzi L, Samanin R. Selective reduction of extracellular dopamine in the rat nucleus accumbens following chronic treatment with DAU 6215, a 5-HT3 receptor antagonist. Neuropharmacology. 1995 Feb;34(2):211-5. PubMed PMID: 7617146. 10: Rizzi CA, Prudentino A, Giraldo E. Effects on general behaviour and neurotransmitter functions of a new 5-hydroxytryptamine3 receptor antagonist with potential therapeutic relevance in central nervous system disturbances. Arzneimittelforschung. 1993 Oct;43(10):1033-41. PubMed PMID: 7903536. 11: Borsini F, Brambilla A, Cesana R, Donetti A. The effect of DAU 6215, a novel 5HT-3 antagonist, in animal models of anxiety. Pharmacol Res. 1993 Feb-Mar;27(2):151-64. PubMed PMID: 8097309. 12: Passani MB, Pugliese AM, Azzurrini M, Corradetti R. Effects of DAU 6215, a novel 5-hydroxytryptamine3 (5-HT3) antagonist on electrophysiological properties of the rat hippocampus. Br J Pharmacol. 1994 Jun;112(2):695-703. PubMed PMID: 8075890; PubMed Central PMCID: PMC1910391. 13: Brambilla A, Ghiorzi A, Pitsikas N, Borsini F. DAU 6215, a novel 5-HT3-receptor antagonist, selectively antagonizes scopolamine-induced deficit in a passive-avoidance task, but not scopolamine-induced hypermotility in rats. J Pharm Pharmacol. 1993 Sep;45(9):841-3. PubMed PMID: 7903377. 14: Malinowska B, Pawlak D, Buczko W. Influence of DAU 6215, a novel 5-HT3 receptor antagonist, on the cardiovascular system in anaesthetized and pithed rats. Agents Actions. 1992 Jul;36(3-4):230-6. PubMed PMID: 1529806. 15: Dumuis A, Sebben M, Monferini E, Nicola M, Turconi M, Ladinsky H, Bockaert J. Azabicycloalkyl benzimidazolone derivatives as a novel class of potent agonists at the 5-HT4 receptor positively coupled to adenylate cyclase in brain. Naunyn Schmiedebergs Arch Pharmacol. 1991 Mar;343(3):245-51. PubMed PMID: 1650917. 16: Baxter GS, Clarke DE. Benzimidazolone derivatives act as 5-HT4 receptor ligands in rat oesophagus. Eur J Pharmacol. 1992 Mar 3;212(2-3):225-9. PubMed PMID: 1601064. 17: Turconi M, Nicola M, Quintero MG, Maiocchi L, Micheletti R, Giraldo E, Donetti A. Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT3 receptor antagonists. J Med Chem. 1990 Aug;33(8):2101-8. PubMed PMID: 1695682. 18: Pitsikas N, Brambilla A, Borsini F. Effect of DAU 6215, a novel 5-HT3 receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task. Pharmacol Biochem Behav. 1994 Jan;47(1):95-9. PubMed PMID: 8115433. 19: Prisco S, Pessia M, Ceci A, Borsini F, Esposito E. Chronic treatment with DAU 6215, a new 5-HT3 receptor antagonist, causes a selective decrease in the number of spontaneously active dopaminergic neurons in the rat ventral tegmental area. Eur J Pharmacol. 1992 Apr 7;214(1):13-9. PubMed PMID: 1582449.